Fluarix Clears FDA; GSK Buys Vaccine Manufacturing Plant From Wyeth

GlaxoSmithKline is expanding its vaccine manufacturing capability as it prepares for its flu vaccine Fluarix to enter the U.S. market and in anticipation of several vaccine approvals over the next few years